Your browser is no longer supported. Please, upgrade your browser.
Settings
MDVN Medivation, Inc. daily Stock Chart
MDVN [NASD]
Medivation, Inc.
Index- P/E18.32 EPS (ttm)1.56 Insider Own1.10% Shs Outstand163.71M Perf Week-6.48%
Market Cap4.68B Forward P/E20.37 EPS next Y1.40 Insider Trans-4.50% Shs Float161.81M Perf Month-25.57%
Income266.40M PEG0.28 EPS next Q0.28 Inst Own94.90% Short Float2.33% Perf Quarter-30.51%
Sales840.20M P/S5.57 EPS this Y682.10% Inst Trans0.52% Short Ratio2.00 Perf Half Y-42.23%
Book/sh4.14 P/B6.90 EPS next Y41.72% ROA28.10% Target Price51.81 Perf Year-44.54%
Cash/sh2.99 P/C9.57 EPS next 5Y66.05% ROE50.30% 52W Range26.41 - 70.79 Perf YTD-40.88%
Dividend- P/FCF18.05 EPS past 5Y42.10% ROI44.40% 52W High-59.63% Beta0.96
Dividend %- Quick Ratio3.70 Sales past 5Y59.30% Gross Margin- 52W Low8.22% ATR2.64
Employees485 Current Ratio3.70 Sales Q/Q30.00% Oper. Margin37.60% RSI (14)31.24 Volatility8.41% 7.97%
OptionableYes Debt/Eq0.11 EPS Q/Q-2.10% Profit Margin31.70% Rel Volume1.44 Prev Close29.41
ShortableYes LT Debt/Eq0.00 EarningsFeb 25 AMC Payout0.00% Avg Volume1.89M Price28.58
Recom2.20 SMA20-15.26% SMA50-28.13% SMA200-40.57% Volume2,715,852 Change-2.82%
Feb-01-16Reiterated Wedbush Outperform $59 → $47
Jan-27-16Downgrade Canaccord Genuity Buy → Hold $90 → $45
Jan-21-16Initiated Credit Suisse Outperform
Nov-10-15Reiterated Maxim Group Buy $74 → $54
Nov-09-15Reiterated RBC Capital Mkts Sector Perform $50 → $40
Nov-06-15Reiterated UBS Buy $74 → $68
Nov-06-15Reiterated RBC Capital Mkts Sector Perform $50 → $40
Sep-28-15Reiterated Maxim Group Buy $171 → $74
Sep-16-15Initiated Nomura Buy
Sep-03-15Initiated Citigroup Neutral
Aug-25-15Reiterated UBS Buy $145 → $148
Jul-30-15Reiterated Stifel Buy $146 → $107
Jun-04-15Reiterated Maxim Group Buy $155 → $168
May-08-15Reiterated UBS Buy $130 → $142
May-08-15Reiterated Maxim Group Buy $126 → $155
Apr-20-15Downgrade Credit Suisse Outperform → Neutral
Apr-08-15Reiterated Canaccord Genuity Buy $132 → $180
Mar-30-15Reiterated Maxim Group Buy $126 → $163
Mar-27-15Reiterated Barclays Overweight $133 → $150
Mar-25-15Reiterated Brean Capital Buy $125 → $142
Feb-11-16 04:10PM  Medivation Announces Fourth Quarter and Year-End 2015 Financial Results Teleconference on February 25, 2016 Marketwired
Feb-05-16 08:00AM  Technical Recap on Biotechnology Equities -- Biogen, Medivation, Grifols, and Agios Pharma Accesswire
Feb-03-16 06:40AM  Why Medivation, Inc. Shares Crashed 32% in January at Motley Fool
Feb-02-16 09:04AM  Ignore Regeneron Pharmaceuticals, Inc: Here Are 3 Better Buys Right Now at Motley Fool -5.37%
Jan-29-16 06:10AM  MEDIVATION, INC. Files SEC form 8-K, Regulation FD Disclosure
Jan-27-16 04:23PM  Medivation to Present at Leerink Partners 5th Annual Global Healthcare Conference at noodls
04:10PM  Medivation to Present at Leerink Partners 5th Annual Global Healthcare Conference Marketwired
03:32PM  Opposing Views on Medivation News and Xtandi
08:49AM  Medivation downgraded by Canaccord Genuity
Jan-26-16 04:22PM  Journal of Clinical Oncology Publishes Results From the STRIVE Trial of Enzalutamide Compared to Bicalutamide in Castration-Resistant Prostate Cancer at noodls
04:10PM  Journal of Clinical Oncology Publishes Results from the STRIVE trial of enzalutamide Compared to bicalutamide in Castration-resistant Prostate Cancer PR Newswire
04:10PM  Journal of Clinical Oncology Publishes Results From the STRIVE Trial of Enzalutamide Compared to Bicalutamide in Castration-Resistant Prostate Cancer Marketwired
02:22PM  What Johnson & Johnson's Earnings Mean for Biotech Stocks at Barrons.com
01:13PM  Weekly Insider Sells: Medivation, JPMorgan Chase, Stryker, Sabre
Jan-25-16 06:32AM  MEDIVATION, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-21-16 09:44AM  Medivation (MDVN) Stock Gets Outperform Rating at Credit Suisse at TheStreet
Jan-14-16 07:11AM  Astellas Pharma Europe: Lancet Oncology Publishes Results from the Phase 2 TERRAIN Trial of Enzalutamide Compared to Bicalutamide in Metastatic Castration-Resistant Prostate Cancer Business Wire
Jan-13-16 06:31PM  Lancet Oncology Publishes Results from the Phase 2 TERRAIN Trial of enzalutamide Compared to bicalutamide in Metastatic Castration-Resistant Prostate Cancer PR Newswire
06:31PM  Lancet Oncology Publishes Results From the Phase 2 TERRAIN Trial of Enzalutamide Compared to Bicalutamide in Metastatic Castration-Resistant Prostate Cancer Marketwired
Jan-12-16 01:38PM  Investors Cant Get Enough of These 4 Stocks Today at Insider Monkey +6.17%
07:03AM  3 Biotech Stocks to Buy in January at Motley Fool
07:01AM  Trending Now: MDVN
Jan-11-16 04:43PM  No JP Morgan Conference Love for Ionis Pharmaceuticals Inc, Geron Corporation, and Medivation Inc at Motley Fool -11.20%
07:02AM  MEDIVATION, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial S
07:00AM  Medivation Names Marion McCourt Chief Operating Officer Marketwired
Jan-10-16 01:40PM  Why Medivation, Inc. Jumped 13% in December at Motley Fool
Jan-08-16 08:20AM  Medivation, Inc. breached its 50 day moving average in a Bearish Manner : January 8, 2016
Jan-07-16 07:00AM  NanoString Technologies Enters Into Collaboration Agreement With Medivation and Astellas to Develop Novel Companion Diagnostic Test Marketwired -7.26%
Jan-04-16 04:10PM  Medivation to Present at J.P. Morgan Healthcare Conference Marketwired
01:00PM  Triangle Stock Breakouts to Kick Off 2016 at Investopedia
Dec-25-15 08:06AM  Medivation Initiates Phase 2 Trial of MDV9300: Stock Rises 5.7%
Dec-21-15 08:19AM  Top Biotech Stocks to Buy in 2016 at Motley Fool +5.66%
07:00AM  Medivation Initiates Pivotal Clinical Trial of MDV9300 in Diffuse Large B-Cell Lymphoma Marketwired
Dec-18-15 04:44PM  MEDIVATION, INC. Files SEC form 8-K/A, Financial Statements and Exhibits
Dec-17-15 08:38AM  Medivation, Inc. breached its 50 day moving average in a Bullish Manner : December 17, 2015
Dec-08-15 01:17PM  MEDIVATION, INC. Financials
Dec-07-15 05:20PM  MEDIVATION, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Dec-02-15 08:55PM  5 Top Stocks to Buy in December at Motley Fool
08:49AM  Medivation, Inc. breached its 50 day moving average in a Bullish Manner : December 2, 2015
07:30AM  Can Lightning Strike Three Times? Prostate Cancer Drug Developer Gets $53M To Find Out at Forbes
Nov-29-15 12:36PM  Medivation Inc (MDVN): Are Hedge Funds Right About This Stock? at Insider Monkey
Nov-25-15 09:04AM  Johnson & Johnson's Latest FDA Approval Could Spell Problems for Amgen at Motley Fool
Nov-23-15 10:07AM  3 Value Stocks Near 52-Week Lows Worth Buying at Motley Fool
Nov-13-15 12:30PM  Mariner Investment Groups Top Biotech Stock Picks For Q4 at Insider Monkey
Nov-10-15 12:54PM  [$$] Still Motivated for Medivation Shares at Barrons.com
Nov-06-15 04:10PM  Medivation Announces Participation at Upcoming Investor Conference Marketwired -9.23%
02:09PM  Medivation, Inc. Value Analysis (NASDAQ:MDVN) : November 6, 2015
10:01AM  Medivation, Inc. breached its 50 day moving average in a Bearish Manner : November 6, 2015
06:13AM  MEDIVATION, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial Statements and Exh
12:46AM  Edited Transcript of MDVN earnings conference call or presentation 5-Nov-15 9:30pm GMT
Nov-05-15 07:39PM  Medivation tops Street 3Q forecasts
04:30PM  Medivation Inc Earnings Call scheduled for 4:30 pm ET today
04:19PM  MEDIVATION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:10PM  Medivation Reports Third Quarter 2015 Financial Results Marketwired
07:07AM  Q3 2015 Medivation Inc Earnings Release - After Market Close
Nov-02-15 07:34AM  3 Stocks to Buy Now in Biotech at Motley Fool +5.59%
Oct-31-15 03:29PM  The Secret is Out: This is the Marvel Powering Biotech
Oct-30-15 11:24AM  XBI Fell the Most as the Small-Caps Took a Hit -10.05%
06:21AM  MEDIVATION, INC. Files SEC form 8-K, Other Events
Oct-28-15 02:01PM  These Are Apex Capitals Top Biotech Stock Picks at Insider Monkey
07:57AM  Wild Short Interest Swings For Three Top Biotech Stocks
Oct-27-15 01:25PM  Medivation, Inc. Value Analysis (NASDAQ:MDVN) : October 27, 2015
Oct-26-15 04:44PM  MEDIVATION, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Oblig
12:49PM  Medivation, Inc. breached its 50 day moving average in a Bullish Manner : October 26, 2015
Oct-24-15 01:02PM  Better Buy Now: Medivation Inc vs Jazz Pharmaceuticals at Motley Fool
Oct-22-15 04:10PM  Medivation Announces Third Quarter 2015 Financial Results Teleconference on November 5, 2015 Marketwired
11:06AM  Bluebird Drags Down Biotechnologys Top 10 Mid-Cap Stocks
Oct-20-15 07:21AM  3 Cancer Companies to Watch Closely in 2016 at Motley Fool
Oct-18-15 07:02AM  J&J's Earnings May Be Good News for Bristol-Myers Squibb and Medivation at Motley Fool
Oct-16-15 12:45PM  Will Gilead Sciences Beat Earnings Forecasts? at Barrons.com
Oct-14-15 12:01PM  How This Biotech Stock Hopes to Become More Than a One Trick Pony at Motley Fool
Oct-12-15 03:17PM  Wild Short Interest Swings For These Three Biotech Stocks
Oct-07-15 12:07PM  IBBs Top Ten Mid-Cap Stocks Underperformed Last Week
07:02AM  MEDIVATION, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial Statements and Exh
Oct-02-15 04:07PM  ALNY and XON Drag Down Mid-Cap Stocks Last Week
03:00PM  Where's the Best Risk-Reward in Biotech? at Barrons.com
Sep-30-15 02:43PM  Street Talk: CP, LOW & more +8.56%
Sep-29-15 04:16PM  MEDIVATION, INC. Files SEC form 8-K, Change in Directors or Principal Officers
04:10PM  Medivation Announces Management Changes Marketwired
01:08PM  Medivation and Bluebird Led IBBs Mid-Cap Stocks Last Week
Sep-28-15 02:00PM  Genomic Health Posts Positive Breast Cancer Trial Results
Sep-26-15 05:00AM  Updated Enzalutamide Data in Triple-Negative Breast Cancer Presented at the 2015 European Cancer Congress Marketwired
Sep-25-15 01:35PM  Myriad Genetics Posts Positive Data on Oncology Tests -7.55%
Sep-24-15 09:30AM  Medivation, Greenbrier, Camden Property Trust, Silver Bay Realty Trust and Mid-America Apartment Communities highlighted as Zacks Bull and Bear of the Day
09:04AM  Bull of the Day: Medivation (MDVN)
Sep-22-15 12:58PM  ETFs with exposure to Medivation, Inc. : September 22, 2015
10:17AM  Medivation, Inc. breached its 50 day moving average in a Bearish Manner : September 22, 2015
Sep-21-15 05:27PM  Amgen's Kyprolis Label Expansion Under Priority Review
03:35PM  BioDelivery Up, Opioid Dependence Treatments in Focus
09:30AM  The Zacks Analyst Blog Highlights: Medivation, Gilead Sciences, Regeneron Pharmaceuticals and Anthera Pharmaceuticals
Sep-18-15 10:39AM  Yellen Doesn't Raise Rates: 4 Biotech Stocks to Buy
06:05AM  MEDIVATION, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance
Sep-16-15 07:03AM  Splits Calendar: Medivation splits before market open today (2:1 ratio)
07:00AM  Medivation Effects a Stock Dividend on Its Common Stock Marketwired
Sep-15-15 06:02PM  Medivation Upgraded to Strong Buy, Perfect for Your Portfolio
Sep-09-15 06:04AM  MEDIVATION, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Sep-08-15 04:05PM  A Portfolio To Support Cancer Treatments In Time For Prostate Cancer Awareness Month
01:22PM  UBS: Biotech Will Continue To Outperform In 2015
Sep-03-15 04:10PM  Medivation Announces Participation at Upcoming Investor Conference Marketwired
Aug-27-15 12:57PM  Medivation, Inc. Earnings Q2, 2015
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients. The company's prostate cancer clinical trials include STRIVE, which is in Phase II clinical trial; PROSPER and EMBARK for which enrollment is ongoing for the Phase III clinical trial; PLATO, which is in the Phase IV clinical trial; AFFIRM and PREVAIL that have completed enrollment for the Phase III clinical trial; and TERRAIN for which enrollment is completed for the Phase II clinical trial. Its breast cancer clinical trials comprise AR+, TNBC, ER+ or PgR+ and HER2 Normal, and AR+ HER2 Amplified that are in Phase II clinical trials. It has collaboration agreement with Astellas Pharma, Inc. for the development, manufacture, and commercialization of XTANDI; and License and Manufacturing and supply agreement with CureTech, Ltd. for the development, manufacture, and commercialization of biologic molecules. The company is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hung DavidPresident and CEOFeb 04Sale31.186,350197,9931,504,654Feb 05 07:05 PM
Machado Clarence PatrickDirectorJan 19Option Exercise3.3775,000252,525141,156Jan 21 05:45 PM
Machado Clarence PatrickDirectorJan 19Sale37.3475,0002,800,56266,156Jan 21 05:45 PM
Lobacki Joseph MChief Commercial OfficerJan 04Sale46.503,065142,52319,365Jan 05 06:14 PM
VERNON W ANTHONYDirectorDec 14Buy40.6915,000610,35028,704Dec 16 05:40 PM
Hung DavidPresident and CEODec 03Sale43.1010,950471,9661,511,004Dec 04 04:36 PM
Hirmand MohammadInterim Chief Medical OfficerDec 03Sale43.401,07546,65531,113Dec 04 04:35 PM
Hirmand MohammadInterim Chief Medical OfficerNov 09Sale41.912329,72232,188Nov 12 06:46 PM
Svoronos DawnDirectorSep 08Sale89.153,100276,36512,117Sep 08 07:39 PM
Machado Clarence PatrickDirectorJun 04Option Exercise9.3936,000337,86067,500Jun 08 06:25 PM
Machado Clarence PatrickDirectorJun 04Sale117.4336,0004,227,47831,500Jun 08 06:25 PM
Bierly RickChief Financial OfficerMay 20Sale130.001,000130,00014,841May 20 06:40 PM
Bierly RickChief Financial OfficerMay 08Sale125.0038548,12515,841May 12 08:07 PM
Bierly RickChief Financial OfficerMay 05Sale125.001,615201,87516,226May 06 07:42 PM
Bierly RickChief Financial OfficerMay 04Sale124.702,170270,60417,841May 06 07:42 PM
Bierly RickChief Financial OfficerApr 15Option Exercise58.103,000174,30023,011Apr 16 05:31 PM
Bierly RickChief Financial OfficerApr 15Sale132.203,000396,60020,011Apr 16 05:31 PM
Rhodes Jennifer JGC & Corporate SecretaryMar 16Sale130.921,390181,97911,090Mar 17 05:37 PM
Rhodes Jennifer JGC & Corporate SecretaryMar 02Option Exercise47.482,00094,96014,480Mar 02 09:16 PM
Svoronos DawnDirectorMar 02Sale119.753,350401,16313,639Mar 04 09:22 PM
Rhodes Jennifer JGC & Corporate SecretaryMar 02Sale122.002,000244,00012,480Mar 02 09:16 PM
Hung DavidPresident and CEOMar 02Sale120.83100,89112,190,609760,977Mar 02 09:15 PM
FALBERG KATHRYN EDirectorFeb 27Buy117.6725,0002,941,68425,000Mar 02 09:13 PM
Rhodes Jennifer JGC & Corporate SecretaryFeb 26Option Exercise47.482,00094,96014,480Feb 27 04:56 PM
Hung DavidPresident and CEOFeb 26Sale120.1219,1092,295,373861,868Feb 27 04:55 PM
Rhodes Jennifer JGC & Corporate SecretaryFeb 26Sale119.293,089368,50211,391Feb 27 04:56 PM